Mitochondria: A therapeutic target in neurodegeneration

Paula I. Moreira, Xiongwei Zhu, Xinglong Wang, Hyoung gon Lee, Akihiko Nunomura, Robert B. Petersen, George Perry, Mark A. Smith

Research output: Contribution to journalReview articlepeer-review

200 Scopus citations

Abstract

Mitochondrial dysfunction has long been associated with neurodegenerative disease. Therefore, mitochondrial protective agents represent a unique direction for the development of drug candidates that can modify the pathogenesis of neurodegeneration. This review discusses evidence showing that mitochondrial dysfunction has a central role in the pathogenesis of Alzheimer's, Parkinson's and Huntington's diseases and amyotrophic lateral sclerosis. We also debate the potential therapeutic efficacy of metabolic antioxidants, mitochondria-directed antioxidants and Szeto-Schiller (SS) peptides. Since these compounds preferentially target mitochondria, a major source of oxidative damage, they are promising therapeutic candidates for neurodegenerative diseases. Furthermore, we will briefly discuss the novel action of the antihistamine drug Dimebon on mitochondria.

Original languageEnglish (US)
Pages (from-to)212-220
Number of pages9
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1802
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Keywords

  • Metabolic antioxidant
  • Mitochondria
  • Mitochondria-directed antioxidant
  • Neurodegeneration
  • SS peptide

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Mitochondria: A therapeutic target in neurodegeneration'. Together they form a unique fingerprint.

Cite this